New Securities Class Action Lawsuit Filed Against Gritstone Bio


Gainey McKenna & Egleston has announced the filing of a securities class action lawsuit against Gritstone bio, Inc. The lawsuit, filed in the United States District Court for the Northern District of California, represents all individuals and entities who purchased securities of Gritstone between March 9, 2023, and February 29, 2024.

The lawsuit alleges that Gritstone made false and misleading statements, as well as failed to disclose important information to investors. It is claimed that Gritstone misrepresented its ability to launch the Phase 2b CORAL Study within the stated timeframe. This, in turn, allegedly impaired the company’s ability to secure external funding for the study, negatively impacting its balance sheet and cash position. As a result, Gritstone is accused of overstating its capacity to successfully develop and commercialize its products.

Investors who bought or acquired shares of Gritstone during the Class Period are encouraged to contact the Firm before the lead plaintiff motion deadline on August 6, 2024. The lead plaintiff will act as the representative party for other class members in directing the litigation. For more information about the lawsuit, interested parties can reach out to

Gainey McKenna & Egleston, the law firm that filed the lawsuit, or visit their website.

In addition to the information provided in the article, it is important to consider current market trends and forecasts related to Gritstone Bio. Gritstone is a biotechnology company that focuses on developing personalized cancer immunotherapies. As the field of cancer immunotherapy continues to grow, there is increased interest and investment in companies like Gritstone that are developing innovative treatments.

According to a report by Grand View Research, the global cancer immunotherapy market is expected to reach $126.9 billion by 2026, growing at a compound annual growth rate of 9.6%. This indicates that there is significant potential for companies like Gritstone to succeed in the market.

However, there are also key challenges and controversies associated with the subject. One challenge that Gritstone Bio and other biotechnology companies face is the high costs and long development timelines associated with bringing new treatments to market. The process of conducting clinical trials and obtaining regulatory approvals can be lengthy and expensive, which can impact a company’s financial position.

Another challenge is the competitive landscape. Gritstone operates in a highly competitive industry with other biotechnology companies also developing cancer immunotherapies. Competition for funding, partnerships, and market share can be intense, and success is not guaranteed.

It is important for investors to consider both the advantages and disadvantages associated with investing in Gritstone Bio or any other biotechnology company. The potential advantages include the opportunity to invest in a promising sector with significant growth potential. Successful development and commercialization of cancer immunotherapies could lead to substantial financial returns. However, the disadvantages include the inherent risks associated with investing in biotechnology, such as clinical trial failures, regulatory challenges, and competition.

For more information on Gritstone Bio, interested parties can visit the company’s official website at It is always recommended to conduct thorough research and consult with a financial advisor before making any investment decisions.

– Grand View Research. (2021). Cancer Immunotherapy Market Size, Share & Trends Analysis Report By Type. Retrieved from